View all press releases

Tetra Bio-Pharma Engages energi PR as its Public Relations Firm


OTTAWA, ON / ACCESSWIRE / May 8, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has engaged energi PR Inc. as its public relations firm, led by CEO, Carol Levine a seasoned public relations professional. The firm will concentrate on the implementation of a communication strategy including media relations, virtual town halls, social media and corporate communications.

"I am very pleased and excited to engage energi PR as our public relations firm. They excel at corporate communications and building media relationships and do so with a solid understanding of Tetra's culture and mission. I have worked with Carol for the last 15 years and she has always demonstrated excellent leadership at media outreach and issues management, and where we benefited from clear guidance in the past, this experience was a critical factor for Tetra when appointing them for our PR strategy." stated Steeve Néron, Chief Operating Officer at Tetra.

The agreement with energi PR was effective May 1, 2020 for a term of 6 months. energi PR will be paid fees of $8,000 per month for its services. energi PR will complement Alpha Bronze efforts, while Alpha Bronze will focus on investor's relations, energi PR will concentrate on media relations and corporate communications.

About energi PR Inc.

energi PR Inc. is an independently owned PR consulting agency providing world-class insights, local market knowledge, strategy and implementation through public relations and integrated social and digital marketing communications. Celebrating its' 30th anniversary this year, the firm specializes in consumer health and medical science communications having represented some of the worlds most recognized consumer and pharmaceutical brands across a range of therapeutic categories including oncology, vision health, pain and immune-mediated diseases. In 2014 they were pioneers in talking about cannabinoids to mainstream media. energi PR, with offices in Toronto and Montreal, is the sole Canadian affiliate of GLOBALHealthPR, the largest independent medical communications agency partnership in the world with more than 40 offices on six continents. For more information visit:

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX-V:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit:

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of any product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.:

Investor Contact:

Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433

Media Contact:

energi PR
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256

SOURCE: Tetra Bio-Pharma

View source version on

Categories: Press Releases
View all press releases